Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma

NCT01616199 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

24

Enrollment

INDUSTRY

Sponsor class

Stopped slow accrual

Conditions

Advanced BRAF-mutant Cancers

Interventions

DRUG: PX-866
DRUG: vemurafenib

Sponsor

Cascadian Therapeutics Inc.